Aptose reports Q4 net loss $10.0M; cash runway into Q1 2024; tuspetinib expansion trial underway

Aptose Biosciences Inc.

Q4 net loss $10.0M ($0.11/sh) vs $24.3M loss year ago; FY2022 net loss $41.8M ($0.45/sh) vs $65.4M.
Cash and investments $47.0M at Dec 31, 2022; expects funding into Q1 2024.
APTIVATE Phase 1/2 expansion trial for tuspetinib initiated; monotherapy and TUS/VEN combination arm enrolling.
Tuspetinib monotherapy showed 29% CR/CRh in RAS-mutated AML patients during dose escalation.
Luxeptinib G3 formulation shows improved bioavailability; continuous dosing ongoing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported the quarter ended December 31, 2022 results: net income $10.0 million, EPS ($0.11 per share).

Period: the quarter ended December 31, 2022
Net income: $10.0 million
EPS: ($0.11 per share)
Result: reported results

Exact text from the filing

The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported the year ended December 31, 2022 results: net income $41.8 million, EPS ($0.45 per share).

Period: the year ended December 31, 2022
Net income: $41.8 million
EPS: ($0.45 per share)
Result: reported results

Exact text from the filing

The net loss for the year ended December 31, 2022, was $41.8 million ($0.45 per share) compared with $65.4 million ($0.73 per share) for the year ended December 31, 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001869

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.